SOURCE: BIOLASE Technology, Inc.

BIOLASE Technology, Inc.

July 14, 2011 09:00 ET

BIOLASE Issued New Patents That Strengthen Its Expansion Into the Treatment of Eye Conditions, Including Presbyopia

Two New Patents Increase Worldwide Portfolio to 147 Issued Patents and 141 Patents Pending

IRVINE, CA--(Marketwire - Jul 14, 2011) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has issued BIOLASE two new patents covering the use of its laser technologies for treating various conditions of the eye, including presbyopia.

Presbyopia is the inability to focus sharply for near vision. It currently affects more than 100 million people in the U.S. and more than 2 billion people worldwide.

Patent number 7,967,017, titled "Methods for Treating Eye Conditions," includes 29 claims and introduces a new strategy for identifying optimal treatment zones for the reversal of presbyopia, the age-related loss of near vision that affects everyone in mid-life. Patent number 7,909,040, also titled "Methods for Treating Eye Conditions," includes 10 claims and relates to the shape of the treatment laser beam and specific ablative patterns for treating presbyopia.

These are BIOLASE's seventh and eighth U.S. patents to be issued under the "Methods for Treating Eye Conditions" patent family. BIOLASE currently holds a total of 11 issued and 22 pending U.S. and international patents in four patent families in the field of ophthalmology. BIOLASE believes that these U.S. and international ophthalmic patents give the Company one of the widest ranges of applications and coverage in the field.

Federico Pignatelli, Chairman and CEO, commented, "These new patents significantly enhance our IP position in ophthalmology, a market segment that we are aggressively pursuing. I am very pleased with BIOLASE's continued efforts and success in increasing and protecting its intellectual property portfolio."

Chief Technology Officer Dmitri Boutoussov, PhD, said, "One of our key strategic plans is to create a diversified and balanced IP portfolio that can be used in various ways to stimulate further adoption of our lasers in dentistry and medicine. These new ophthalmic patents substantiate our success in doing so. We know that many medical professionals and their patients will significantly benefit from the use of our technology and we are working towards that goal."

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at, Twitter at, and YouTube at

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti
    Allen & Caron